CUSIP 52886X107COMLXEOQ4 2025
Aggregate 13F value by quarter
Multi-quarter trend — upgrade to see history
UpgradeQ4 2025
144 funds hold this security · Q4 2025
| # | Fund | Shares | Value | Δ Shares | Activity |
|---|---|---|---|---|---|
| 1 | Janus Henderson Group PLC | 5.51M | $54.67M | −595.9K | Reduced |
| 2 | Ra Capital Management, L.P. | 5.00M | $49.65M | +5.00M | New |
| 3 | Blackrock, Inc. | 4.91M | $48.73M | +2.74M | Added |
| 4 | Paradigm Biocapital Advisors LP | 4.76M | $47.30M |
| +4.76M |
| New |
| 5 | Vestal Point Capital, LP | 4.47M | $44.44M | +1.23M | Added |
| 6 | Frazier Life Sciences Management, L.P. | 4.42M | $43.94M | 0 | Held |
| 7 | Vanguard Group Inc | 3.89M | $38.67M | +1.67M | Added |
| 8 | Citadel Advisors LLC | 3.77M | $37.48M | +55.3K | Added |
| 9 | Avoro Capital Advisors LLC | 3.30M | $32.77M | +3.30M | New |
| 10 | Affinity Asset Advisors, LLC | 3.20M | $31.78M | −670.5K | Reduced |
See every fund holding Lexeo Therapeutics Inc, with full quarter-over-quarter share changes.
Unlock all holders